BMP-2: A culprit for anemia in myeloma

Blood

Volumn 116, Issue 18, 2010, Pages 3383-3384

  Ludwig, Heinz ^a  

^a Center for Oncology and Hematology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYELOMA AGENT; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CYTOKINE; ERYTHROPOIETIN; FERROPORTIN; HEPCIDIN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; PROTEIN BCL XL; PROTEIN P21; PROTEIN P27; RECOMBINANT ERYTHROPOIETIN; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANEMIA; BINDING SITE; CANCER PATIENT; CARTILAGE; CELL CYCLE ARREST; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DILUTIONAL ANEMIA; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG TARGETING; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; GENE CONSTRUCT; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HYPERVOLEMIA; IRON ABSORPTION; IRON METABOLISM; LIVER CELL; MACROPHAGE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; NOTE; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 78149340651     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-302349     Document Type: Note

References (10)

1. Maes K, Nemeth E, Roodman, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116(18):3635-3644.
2. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11):3262-3267.
3. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev. 1996;6(4):432-438.
4. Kawamura C, Kizaki M, Yamato K, et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood. 2000;96(6):2005-11.
5. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ. Stimulation of BMP-2expression by pro-inflammatory cytokines IL-1 and TNF-alpha in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am. 2003;85-A(suppl 3):59-66.
6. Katodritou E, Ganz T, Terpos E, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol. 2009;84(8):524-526.
7. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24-38.
8. Ludwig H, Pohl G, Osterborg A. Anemia in multiple myeloma. Clin Adv Hematol Oncol. 2004;2(4):233-241.
9. Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood. 2007;109(9):4038-4044. (Pubitemid 46641759)
10. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616-3624.